| Name | Title | Contact Details |
|---|
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.
Imperial Clinical Research Services is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Artemisia BioMedical is a Renton, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mascoma Corporation is a Brighton, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information